Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8 + T cells via increasing intratumoral CXCL10.

MLA

Huang, Mu-Yang, et al. “Ginsenoside Rh2 Augmented Anti-PD-L1 Immunotherapy by Reinvigorating CD8 + T Cells via Increasing Intratumoral CXCL10.” Pharmacological Research, vol. 198, Dec. 2023, p. 106988. EBSCOhost, https://doi.org/10.1016/j.phrs.2023.106988.

APA

Huang, M.-Y., Chen, Y.-C., Lyu, W.-Y., He, X.-Y., Ye, Z.-H., Huang, C.-Y., He, X.-L., Chen, X., Chen, X., Zhang, B., Kai, G., Zhang, X., Li, T., Huang, M., & Lu, J.-J. (2023). Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8 + T cells via increasing intratumoral CXCL10. Pharmacological Research, 198, 106988. https://doi.org/10.1016/j.phrs.2023.106988

Chicago

Huang, Mu-Yang, Yu-Chi Chen, Wen-Yu Lyu, Xin-Yu He, Zi-Han Ye, Can-Yu Huang, Xin-Ling He, et al. 2023. “Ginsenoside Rh2 Augmented Anti-PD-L1 Immunotherapy by Reinvigorating CD8 + T Cells via Increasing Intratumoral CXCL10.” Pharmacological Research 198 (December): 106988. doi:10.1016/j.phrs.2023.106988.